September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Outcomes of penetrating keratoplasty following ex vivo expanded autologous limbal stem cell transplantation (ALSCT)
Author Affiliations & Notes
  • Francisco C Figueiredo
    Ophthalmology, Royal Victoria Infirmary/Newcastle University, Newcastle upon Tyne, United Kingdom
    Institute of Genetic Medicine , Newcastle University, Newcastle upon Tyne, United Kingdom
  • Oliver Baylis
    Ophthalmology, Royal Victoria Infirmary/Newcastle University, Newcastle Upon Tyne, United Kingdom
  • Borja Salvador-Culla
    Ophthalmology, Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom
  • Majlinda Lako
    Institute of Genetic Medicine , Newcastle University, Newcastle upon Tyne, United Kingdom
  • Gustavo S Figueiredo
    Ophthalmology, Royal Victoria Infirmary/Newcastle University, Newcastle Upon Tyne, United Kingdom
    Institute of Genetic Medicine , Newcastle University, Newcastle upon Tyne, United Kingdom
  • Footnotes
    Commercial Relationships   Francisco Figueiredo, None; Oliver Baylis, None; Borja Salvador-Culla, None; Majlinda Lako, None; Gustavo Figueiredo, None
  • Footnotes
    Support  MRC UK Grant G0900879
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 891. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Francisco C Figueiredo, Oliver Baylis, Borja Salvador-Culla, Majlinda Lako, Gustavo S Figueiredo; Outcomes of penetrating keratoplasty following ex vivo expanded autologous limbal stem cell transplantation (ALSCT). Invest. Ophthalmol. Vis. Sci. 2016;57(12):891.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Total limbal stem cell deficiency (TLSCD) is mostly caused by ocular surface burns and leads to severe visual impairment in addition to other symptoms. We are conducting a prospective phase 2 clinical trial for the treatment of 23 patients with unilateral TLSCD with ex vivo expanded ALSCT to restore their corneal epithelium. These patients can then undergo a penetrating keratoplasty (PKP) to restore their sight if required. We aim to evaluate the outcomes of PKP in this group of patients

Methods : Consecutive patients involved in our ALSCT clinical trial were included (n=23). All patients underwent previous ALSCT as per our published methods and were followed up for up to 3 years. Patients underwent PKP at least 1 year post-ALSCT. Post-operative treatment included a reducing regimen of gutta prednisolone 1%. Post-operative BCVA and refraction were recorded at least every 3 months. Corneal impression cytology was taken at 6-monthly intervals throughout our ALSCT clinical trial, and the trephined corneal button was sent for histological examination, immunohistochemistry (CK12, CK13, p63, ABCG2, Ki67) and EM. PKP complications, including rejection and failures were reported. PKP survival was estimated by Kaplan-Meier survival probability estimates

Results : Corneal impression cytology prior to PKP confirmed complete restoration of corneal epithelium in all patients. Thirteen patients (12 males, 1 female; 6 right eyes; mean age 40 years, range 22-77, SD 16) underwent PKP post-ALSCT (mean time from ALSCT to PKP 16.9 months, range 11.9-23.5, SD 3.5); 8 further patients are awaiting PKP and 2 patients will not require PKP due to good BCVA. Two patients developed endothelial rejection, both leading to graft failure. There were no other graft failures or post-op complications; 12-month graft survival is 90% (95%CI 50.8-98.7%). Pre-op mean BCVA (logMAR) was 1.18 (range 0.48-1.7, SD 0.47), significantly improving to a post-op mean BCVA of 0.35 (range 0-0.78, SD 0.25, p<0.0001) with a mean follow-up of 11.4 months post-PKP (range 3-19, SD 5.3)

Conclusions : Most patients (21/23) with unilateral TLSCD treated with ALSCT require a PKP for visual rehabilitation. Despite this cohort being "high risk" for PKP (i.e. pre-op inflammation and neovascularization), visual outcomes as well as rejection rates and graft failure rates are similar to that reported in the literature for routine PKP

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×